# Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults

> **NCT02100917** · PHASE1 · COMPLETED · sponsor: **Meiji Seika Pharma Co., Ltd.** · enrollment: 70 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** DMB-3111
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT02100917
- **Lead sponsor:** Meiji Seika Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-05
- **Final completion:** 2014-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02100917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02100917, "Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02100917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*